The Courier-Mail

CSL profit, world rank­ing still doesn’t please mar­ket

- Business · Finance · Stocks & Markets · Investing · Financial Markets · Tonga · Iceland · Thailand

VAC­CINE gi­ant CSL’s forecast of 5 per cent profit growth in the year ahead has dis­ap­pointed in­vestors.

But the com­pany’s out­look does not in­clude its re­cently pur­chased busi­ness that will make it the world’s sec­ond­largest flu vac­cine maker.

CSL made a net profit of $US1.38 bil­lion ($A1.89 bil­lion) ) in the year to June 30, up 5.5 per cent from a year ear­lier, as rev­enue rose al­most 2 per cent to $US5.63 bil­lion.

The biotech­nol­ogy firm ex­pects sim­i­lar sales growth in the year ahead, and stronger earn­ings per share growth than profit growth.

Chief ex­ec­u­tive Paul Per­reault says healthy de­mand for CSL vac­cines and plasma prod­ucts will drive growth and lift net profit about 5 per cent.

“Our un­der­ly­ing growth is strong and the fun­da­men­tals, our abil­ity to gen­er­ate profit and to grow th the busi­ness, have not changed,” he said said. But CSL’s sha share price, which brie briefly hit $100 a sha share last week, fell $ $2.112.1 to $93 yesterday day. CSL de­clared a fina fi­nal fully-franked divi div­i­dend of US66 , up US6 on the pre pre­vi­ous year.

 ??  ??

Newspapers in English

Newspapers from Australia